Yupelri

News

Zymeworks cuts deal to buy Theravance for $929m in cash

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

News

Theravance axes staff as lead pipeline drug flunks phase 3 t...

Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in a phase 3 trial, cutting 75% of its workforce.

News

UK partners with Eli Lilly on obesity plan

The UK has teamed up with Eli Lilly on initiatives, backed with £85 million in funding, to expand access to treatment for obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks